LXRX - Lexicon Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.3500
+0.0850 (+2.60%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.2650
Open3.2700
Bid3.1400 x 900
Ask0.0000 x 3100
Day's Range3.2400 - 3.4200
52 Week Range1.1300 - 8.3900
Volume672,459
Avg. Volume1,359,062
Market Cap346.976M
Beta (5Y Monthly)1.01
PE Ratio (TTM)2.27
EPS (TTM)1.4750
Earnings DateMar 10, 2020 - Mar 15, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
  • FDA denies appeal of decision over Lexicon Pharma’s diabetes drug
    Yahoo Finance Video

    FDA denies appeal of decision over Lexicon Pharma’s diabetes drug

    Yahoo Finance’s Alexis Christoforous, Brian Sozzi and Ines Ferre discuss the markets at the opening bell on The First Trade.

  • GlobeNewswire

    Lexicon Pharmaceuticals Announces Real-World Data on Telotristat Ethyl’s Antiproliferative Effects in Patients With Carcinoid Syndrome

    Lexicon Pharmaceuticals, Inc. (LXRX), announced today real-world data on XERMELO’s® (telotristat ethyl) antiproliferative effects in patients with carcinoid syndrome that were presented at the American Society for Clinical Oncology (ASCO) 2020 Symposium (January 23-25, San Francisco, CA). XERMELO is approved for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy, but is not currently approved for any other use. Data from a retrospective, pre- and post-design chart review of 200 metastatic neuroendocrine tumor patients who were on standard background therapies and received telotristat ethyl for an average of 12 months in US clinical practice demonstrated significant mean tumor size reduction of 0.59 cm after initiation of telotristat ethyl (p = 0.006).

  • GlobeNewswire

    Lexicon Pharmaceuticals Announces Poster Presentation at the ASCO 2020 Gastrointestinal Cancers Symposium

    THE WOODLANDS, Texas, Jan. 20, 2020 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from a poster highlighting XERMELO® (telotristat ethyl) will be.

  • Is Lexicon Pharmaceuticals (NASDAQ:LXRX) Using Too Much Debt?
    Simply Wall St.

    Is Lexicon Pharmaceuticals (NASDAQ:LXRX) Using Too Much Debt?

    Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

  • Top Biotech Stocks for Q1 2020
    Investopedia

    Top Biotech Stocks for Q1 2020

    These are the biotechnology stocks with the best value, fastest growth, and most momentum for Q1 2020.

  • GlobeNewswire

    Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

    THE WOODLANDS, Texas, Jan. 06, 2020 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at.

  • MarketWatch

    Lexicon shares fall on diabetes study data

    Shares of Lexicon Pharmaceuticals Inc. are down 5% in premarket trading on Friday after the biopharmaceutical company said that its experimental Type 2 diabetes treatment met its primary and secondary endpoints in a late-stage clinical trial. The therapy, Zynquista, is already approved in Europe. Earlier this month, Lexicon said that the Food and Drug Administration had denied a company appeal that the regulator reconsider approving Zynquista as a Type 1 diabetes treatment. The company said Dec. 2 it plans to appeal the decision again. Lexicon's stock is down 33% year-to-date, compared to the S&P 500 , which is up 27%.

  • GlobeNewswire

    Lexicon Pharmaceuticals Announces Topline Phase 3 Data for Sotagliflozin in Type 2 Diabetes

    Lexicon Pharmaceuticals, Inc. (LXRX), today announced topline data from the Phase 3 SOTA-EMPA study for sotagliflozin (Zynquista™) in type 2 diabetes. Sotagliflozin 400 mg achieved the primary endpoint of superiority on A1C reduction versus placebo at Week 26 in patients with type 2 diabetes who have inadequate glycemic control on a dipeptidyl peptidase 4 inhibitor (DPP4i) with or without metformin.

  • Were Hedge Funds Right About Betting On Lexicon Pharmaceuticals, Inc. (LXRX)?
    Insider Monkey

    Were Hedge Funds Right About Betting On Lexicon Pharmaceuticals, Inc. (LXRX)?

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

  • Implied Volatility Surging for Lexicon (LXRX) Stock Options
    Zacks

    Implied Volatility Surging for Lexicon (LXRX) Stock Options

    Investors need to pay close attention to Lexicon (LXRX) stock based on the movements in the options market lately.

  • How Much is Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) CEO Getting Paid?
    Simply Wall St.

    How Much is Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) CEO Getting Paid?

    Lonnel Coats has been the CEO of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) since 2014. This analysis aims first to...

  • GlobeNewswire

    Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211

    Lexicon Pharmaceuticals, Inc. (LXRX), today announced positive topline data from the Phase 1 multiple ascending dose study of LX9211, a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1), in development for the treatment of neuropathic pain. "We are pleased that the initial clinical data for LX9211 in the multiple ascending dose study supports continued advancement of the drug," said Praveen Tyle, Ph.D., executive vice president of research and development at Lexicon. The randomized, double-blind, placebo-controlled, multiple ascending dose Phase 1 study was performed to evaluate the safety, tolerability and pharmacokinetics of orally administered LX9211 in healthy volunteers.

  • GlobeNewswire

    Lexicon Pharmaceuticals Completes Safety Review of Initial Safety Run-in Cohort of TELE-ABC Study, a Phase 2 Clinical Study of Telotristat Ethyl in Biliary Tract Cancer

    THE WOODLANDS, Texas, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX), announced today the completion of a safety review of the initial run-in cohort of the Telotristat Ethyl for Advanced Biliary Tract Cancer, or TELE-ABC, study, which is a Phase 2 clinical study of telotristat ethyl in patients with biliary tract cancer. Telotristat ethyl is a novel, oral tryptophan hydroxylase (TPH) inhibitor approved as XERMELO® for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy alone.

  • Benzinga

    Why Lexicon Pharma Shares Are Moving Lower

    Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) shares were retreating sharply Monday morning on an adverse development with its Type 1 diabetes drug candidate sotagliflozin. The actively traded, small-cap biotech Lexicon said it has been notified by the Office of New Drugs of the FDA that the agency is standing by its prior position and denying the company's appeal of the complete response letter related to its NDA for its Type 1 diabetes drug sotagliflozin. Sotagliflozin, going by the trade name Zynquista, is an oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2.

  • MarketWatch

    UPDATE: Lexicon Pharmaceuticals stock slides 31% after FDA denies appeal of decision relating to diabetes drug

    Lexicon Pharmaceuticals Inc. shares slid 31% in premarket trade Monday, after the company said the U.S. Food and Drug Administration has denied its appeal of a decision relating to a diabetes treatment. The Woodlands, Texas-based company said the FDA denied its appeal of a Complete Response Letter relating to its new drug application for sotagliflozin in type 1 diabetes. The company said it would appeal the decision and will hold a conference call at 8.00 a.m. Eastern. The FDA issued the Complete Response Letter, a ruling that means it cannot accept a NDA in its present form, back in February. Lexicon shares have fallen 47% in 2019, while the S&P 500 has gained 25%.

  • GlobeNewswire

    Lexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDA’s Office of New Drugs for Sotagliflozin in Type 1 Diabetes

    Lexicon Pharmaceuticals, Inc. (LXRX), today announced that the Office of New Drugs of the U.S. Food and Drug Administration (FDA) has reiterated the FDA's prior position and denied Lexicon's appeal of the Complete Response Letter in relation to the New Drug Application for sotagliflozin (ZynquistaTM) in type 1 diabetes. Lexicon management will hold a live conference call today, December 2, 2019, at 8:00 am EST / 7:00 am CST to discuss today’s announcement.

  • Thomson Reuters StreetEvents

    Edited Transcript of LXRX earnings conference call or presentation 7-Nov-19 1:00pm GMT

    Q3 2019 Lexicon Pharmaceuticals Inc Earnings Call

  • Are Investors Undervaluing Lexicon Pharmaceuticals (LXRX) Right Now?
    Zacks

    Are Investors Undervaluing Lexicon Pharmaceuticals (LXRX) Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Top Ranked Value Stocks to Buy for November 13th
    Zacks

    Top Ranked Value Stocks to Buy for November 13th

    Top Ranked Value Stocks to Buy for November 13th

  • Lexicon Pharmaceuticals (LXRX) Q3 Earnings and Revenues Beat Estimates
    Zacks

    Lexicon Pharmaceuticals (LXRX) Q3 Earnings and Revenues Beat Estimates

    Lexicon (LXRX) delivered earnings and revenue surprises of 48.85% and 2146.84%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Lexicon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides a Business Update

    THE WOODLANDS, Texas, Nov. 07, 2019 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended.

  • GlobeNewswire

    Lexicon Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call and Webcast on November 7, 2019

    Lexicon Pharmaceuticals, Inc. (LXRX), will release its third quarter 2019 financial results on Thursday, November 7, 2019 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EST (7:00 a.m. CST) that day to discuss the financial results and to provide a business update.

  • Lexicon Pharmaceuticals (LXRX) to Report Q3 Results: Wall Street Expects Earnings Growth
    Zacks

    Lexicon Pharmaceuticals (LXRX) to Report Q3 Results: Wall Street Expects Earnings Growth

    Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.